

P&T Motion History Multiple Sclerosis Drugs

Drugs reviewed	Motion	Date reviewed	Scan accepted as adequate update	Reiteration of prior motion	Decision
alemtuzumab daclizumab HYP dimethyl fumarate fingolimod glatiramer interferon β 1a IM, SC peginterferon β 1a SC interferon β 1b SC teriflunomide mitoxantrone* natalizumab* ocrelizumab **	<p>After considering the evidence of safety, efficacy and special populations for the treatment of Multiple Sclerosis, I move that alemtuzumab, daclizumab HYP, mitoxantrone, natalizumab, dimethyl fumarate, teriflunomide, fingolimod, glatiramer, ocrelizumab, interferon beta 1B SC, peginterferon β 1a SC, interferon beta 1A IM, and interferon beta 1A SC are safe and efficacious. A product that is safe for use during pregnancy should be made available. The MS Drugs cannot be subject to therapeutic interchange in the Washington preferred drug list for the treatment of Multiple Sclerosis. An oral agent should be included in the list of preferred drugs on the PDL.</p> <p>Motion: Figueroa 2nd: Storhaug</p> <p>Recommend for DERP to do a network analysis.</p>	June 21, 2017	Yes Figueroa Schwilke	No	Passed unanimous

Bold = new this update

*=drugs not reviewed, but carried forward from previous review

**=previously studied by OHSU, now FDA approved, eligible to be preferred

6/22/2017